Stem cells hold key to tackling brain disease

Impact ◽  
2020 ◽  
Vol 2020 (7) ◽  
pp. 67-69
Author(s):  
Yun-Bae Kim ◽  
Ehn-Kyoung Choi ◽  
Hye-Rim Seong ◽  
Sangryong Park
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Neurodegenerative Diseases ◽  
Stem Cell Research ◽  
Central Research Institute ◽  
World Health ◽  
Central Research ◽  
Ache Inhibitors ◽  
The World ◽  
Health Organization

A rapidly ageing global society means a higher prevalence of neurodegenerative diseases. Looking at dementia, for example, the most common form of which is Alzheimer's disease (AD), the World Health Organization estimates that worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. And, it's predicted that this number could rise to 150 million people by the year 2050. It's clear that consistent and continued efforts to explore methods of prevention and treatments are required. Existing treatments include acetylcholinesterase (AChE) inhibitors, antibodies to Aβ and anti-inflammatory agents, but these are not without their drawbacks and limitations and new avenues must be explored. A group of Korean scientists believes that stem cells and regenerative medicine hold the key to alleviating the global burden of neurodegenerative diseases and this is where they are focusing their efforts. The innovative stem cell research being undertaken by Designed Cells Co., Ltd, which is based in Korea, performs important stem cell research geared towards improving life – enabling people to age gracefully and maintain wellbeing – and making treatments for neurodegenerative diseases available to all who need them. Professor James Yun-Bae Kim is CEO of the company and Dr Ehn-Kyoung Choi is Director of the company's Central Research Institute. Through their work, the researchers are collaborating with numerous companies spanning different fields, the team is keen to work with global partners in any field to further expand their work to develop treatments for AD and more widely demonstrate the effectiveness of their research.

scholarly journals Regional differences in general practitioners’ behaviours regarding influenza vaccination: a cross-sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jonathan Arlt ◽  
Kristina Flaegel ◽  
Katja Goetz ◽  
Jost Steinhaeuser
Keyword(s):  
Influenza Vaccination ◽  
General Practitioners ◽  
Personal Characteristics ◽  
Cross Sectional Study ◽  
Central Research Institute ◽  
World Health ◽  
Central Research ◽  
Cross Sectional ◽  
Vaccination Rates ◽  
Health Organization

Abstract Background The World Health Organization recommends vaccination rates of 75% against seasonal influenza for patients over 65 years old. In the 2013/2014 season, the German vaccination rates ranged between 14 and 65%. This study aimed to compare the attitudes, personal characteristics and vaccination behaviours of general practitioners (GPs) in regions with high and low vaccination rates in Germany. Methods In May 2016, a questionnaire was sent to 1594 GPs practising in 16 districts with the highest and the lowest vaccination rates in Western and Eastern Germany as described by the Central Research Institute of Ambulatory Health Care in Germany for the 2013/2014 season. Descriptive statistics and multiple regression analyses were computed to identify potential factors associated with high vaccination rates. Results A total response rate of 32% (515/1594 participants) was observed in the study. GPs reported their attitudes towards vaccination in general and vaccination against influenza as mostly ‘very positive’ (80%, n = 352 and 65%, n = 288, respectively). GPs practising in regions with low vaccination rates reported their attitudes towards vaccinations in general (p = 0.004) and towards influenza vaccination (p = 0.001) more negatively than their colleagues from regions with high vaccination rates. Multiple logistic regression identified an increasing influence of year-dependent changing efficiency on GPs’ influenza rates as the strongest factor for predicting GPs from highly vaccinating regions (OR = 4.31 [1.12–16.60]), followed by the patient’s vaccination refusal despite GP advice due to already receiving a vaccination from another physician (OR = 3.20 [1.89–5.43]) and vaccination information gathering through medical colleagues (OR = 2.26 [1.19–4.29]). Conclusions The results of this study suggest a correlation between GPs’ attitudes and regional vaccination rates. Beneath GPs’ individual attitudes, the regional attitude patterns of patients, colleagues and medical assistants surrounding those GPs seem decisive and should be integrated into future campaigns to increase vaccination rates at a regional level.

scholarly journals An evolution of stem cell research and therapy in Viet Nam

2018 ◽  
Vol 5 (1) ◽  
Author(s):  
Phuc Van Pham ◽  
Ngoc Bich Vu ◽  
Oanh Thuy Huynh ◽  
Mai Thi-Hoang Truong ◽  
Truc Le-Buu Pham ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Research ◽  
Web Of Science ◽  
Scientific Information ◽  
Clinical Applications ◽  
Viet Nam ◽  
Disease Treatment ◽  
Research Activities ◽  
The World

Stem cell research and therapy are one of the most attractive studies in the biomedicine. Not only in the bench, nowadays stem cells but also become the bustling industry. In Vietnam, biomedical scientists started to study and apply stem cells since 1995. From that, Vietnamese scientists got some significant achievements in stem cell research and therapy, especially in stem cell therapy for disease treatment. This report aimed to provide an overview of stem cell research and therapy from 1995 to date. Stem cell research activities were collected and analyzed based on the publications, projects about stem cells in some databases including Web of Science, Google Scholar, Embase, and national scientific information. The results showed that stem cell research and therapy significantly increased from 2009 to date with more publications about stem cells and more clinical applications. With this growth rate, we hope that Vietnam can develop the stem cell industry and become one the stem cell center in the Asian and the world.

scholarly journals Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Mohammad T. Elnakish ◽  
Fatemat Hassan ◽  
Duaa Dakhlallah ◽  
Clay B. Marsh ◽  
Ibrahim A. Alhaider ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Treatment Options ◽  
Cardiac Regeneration ◽  
World Health ◽  
Cardiovascular Research ◽  
Cell Based Therapy ◽  
Management Approaches ◽  
Health Organization

Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6 million. Despite the development of a variety of treatment options, heart failure management has failed to inhibit myocardial scar formation and replace the lost cardiomyocyte mass with new functional contractile cells. This shortage is complicated by the limited ability of the heart for self-regeneration. Accordingly, novel management approaches have been introduced into the field of cardiovascular research, leading to the evolution of gene- and cell-based therapies. Stem cell-based therapy (aka, cardiomyoplasty) is a rapidly growing alternative for regenerating the damaged myocardium and attenuating ischemic heart disease. However, the optimal cell type to achieve this goal has not been established yet, even after a decade of cardiovascular stem cell research. Mesenchymal stem cells (MSCs) in particular have been extensively investigated as a potential therapeutic approach for cardiac regeneration, due to their distinctive characteristics. In this paper, we focus on the therapeutic applications of MSCs and their transition from the experimental benchside to the clinical bedside.

scholarly journals Could Putting the Mesenchymal Stem Cells Technology into Practice Be an Optimistic Therapy for The Critically Ill COVID-19?

2020 ◽  
Vol 4 (3) ◽  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Critically Ill ◽  
World Health ◽  
Magic Bullet ◽  
Functional Versus ◽  
Cell Based Therapy ◽  
The World ◽  
Inflammation Reaction

COVID-19 comes to light, quickly developing status. Daily, we know more about the human new coronavirus (HCoV19), which is extremely infective with heavy pneumonia connected with fast virus reproduction. Emerging in Wuhan China 31 December 2019, the contemporary COVID-19 outbreak has quickly overripe taking place directly between individuals so contagion extending to be a world health emergency at present on pandemic level. The pandemic has had deep impacts on everyday lifetime towards numerous of the world. Presently no therapy, no specified remedies or inoculations are ready to treat the patients with COVID-19 pollution and investigators here and there the globe are jostling to recognize present medication or synthesis that could be functional versus it. Therefore, there is a great unmet requirement for a secure and efficient therapy for COVID-19 contaminated cases, particularly the serious cases. What types of therapies might now assist? What are the lab craft strategies to restraining coronavirus? Ago mid-February, one tactic that has acquired rising attraction is stem cell therapy, curing that have often been saw as a potential magic bullet by despairing patients suffering from degenerative incurable conditions. In plentiful of these diseases, truth has so far to coincide with the hype. The cell based-therapy doings by supporting the body’s precocious refractory reply in an orientation that could goal the coronavirus. Now stem cell-based therapy for COVID-19 is earning incentive in China. The tally of the world emergency has visible governments frequently proclamation the company global to develop in the search for a cure, and the Australian corporate Mesoblast – a global commander in cell-based therapies for a lot of illnesses – are earned recently the approval to start clinical trials of their possess stem cell based product against COVID-19. Taking into consideration that generality of the dead sick people were produced by serious inflammation reaction, it is extremely demanding to advance efficient curative factors and strategies for that cases. I present an accurate lab modality in preparing mesenchymal stem cells (MSCs) which might be a perfect option to cure the seriously sick novel COVID-19 cases. Beneath this situation, I suppose that blood derived MSCs generated from the critically ill novel COVID-19 patient itself (autologous) suggested as a treatment for him. Therefore, my viewpoint spots a modern curative strategy.

Erstes Instrument zur standardisierten Erfassung der Teilhabe Behinderter

2017 ◽  
Vol 79 (07) ◽  
pp. 526-527
Keyword(s):  
World Health Organization ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Menschen Mit Behinderung

Coenen M et al. [Recommendation for the collection and analysis of data on participation and disability from the perspective of the World Health Organization]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 1060–1067 Um eine gleichberechtigte Teilhabe an der Gesellschaft von Menschen mit Behinderung zu ermöglichen, werden zunächst Daten zu vorhandenen Einschränkungen gebraucht. Erst wenn diese detailliert erhoben wurden, können Konzepte zur Beseitigung von Problemen entwickelt werden. Ein standardisiertes Erhebungsinstrument für alle Aspekte der Funktionsfähigkeit fehlte jedoch bisher.

Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS

2020 ◽  
pp. 276-289
Author(s):  
Mobina Fathi ◽  
Kimia Vakili ◽  
Niloofar Deravi
Keyword(s):  
Pregnant Women ◽  
Intrauterine Growth Retardation ◽  
Negative Impact ◽  
World Health ◽  
Wuhan City ◽  
Intrauterine Growth ◽  
Exponential Increase ◽  
The World ◽  
Health Organization ◽  
Respiratory Droplets

Around the end of December 2019, a new beta-coronavirus from Wuhan City, Hubei Province, China began to spread rapidly. The new virus, called SARS-CoV-2, which could be transmitted through respiratory droplets, had a range of mild to severe symptoms, from simple cold in some cases to death in others. The disease caused by SARS-CoV-2 was named COVID-19 by WHO and has so far killed more people than SARS and MERS. Following the widespread global outbreak of COVID-19, with more than 132758 confirmed cases and 4955 deaths worldwide, the World Health Organization declared COVID-19 a pandemic disease in January 2020. Earlier studies on viral pneumonia epidemics has shown that pregnant women are at greater risk than others. During pregnancy, the pregnant woman is more prone to infectious diseases. Research on both SARS-CoV and MERS-CoV, which are pathologically similar to SARS-CoV-2, has shown that being infected with these viruses during pregnancy increases the risk of maternal death, stillbirth, intrauterine growth retardation and, preterm delivery. With the exponential increase in cases of COVID-19 throughout the world, there is a need to understand the effects of SARS-CoV-2 on the health of pregnant women, through extrapolation of earlier studies that have been conducted on pregnant women infected with SARS-CoV, and MERS-CoV. There is an urgent need to understand the chance of vertical transmission of SARS-CoV-2 from mother to fetus and the possibility of the virus crossing the placental barrier. Additionally, since some viral diseases and antiviral drugs may have a negative impact on the mother and fetus, in which case, pregnant women need special attention for the prevention, diagnosis, and treatment of COVID-19.

COVID 19: REALS AND CHALLENGES AGAINST DOCTORS

2020 ◽  
Vol 2 (1) ◽  
pp. 65-87
Author(s):  
Zen Ahmad
Keyword(s):  
Virus Disease ◽  
Clinical Manifestations ◽  
World Health ◽  
Unknown Etiology ◽  
Wuhan City ◽  
Traditional Markets ◽  
Pneumonia Case ◽  
The World ◽  
New Type ◽  
Health Organization

Corona Virus Disease (Covid-19) is a contagious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was discovered in December 2019 in China. This disease can cause clinical manifestations in the airway, lung and systemic. The World Health Organization (WHO) representative of China reported a pneumonia case with unknown etiology in Wuhan City, Hubei Province, China on December 31, 2019. The cause was identified as a new type of coronavirus on January 7, 2020 with an estimated source of the virus from traditional markets (seafood market). ) Wuhan city

Sign in / Sign up

Export Citation Format

Share Document